Environmental and Lifestyle Risk Factors in Gallbladder Carcinogenesis: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Subjects: Gastroenterology & Hepatology
Contributor:
Juan Carlos Roa

Gallbladder cancer (GBC) is an aggressive neoplasm that in an early stage is generally asymptomatic and, in most cases, is diagnosed in advanced stages with a very low life expectancy because there is no curative treatment. Therefore, understanding the early carcinogenic mechanisms of this pathology is crucial to proposing preventive strategies for this cancer. The main risk factor is the presence of gallstones, which are associated with some environmental factors such as a sedentary lifestyle and a high-fat diet. Other risk factors such as autoimmune disorders and bacterial, parasitic and fungal infections have also been described. All these factors can generate a long-term inflammatory state characterized by the persistent activation of the immune system, the frequent release of pro-inflammatory cytokines, and the constant production of reactive oxygen species that result in a chronic damage/repair cycle, subsequently inducing the loss of the normal architecture of the gallbladder mucosa that leads to the development of GBC.

  • gallbladder cancer
  • risk factors
  • carcinogenesis

1. Introduction

Gallbladder cancer (GBC) is a neoplasm that causes around 84,695 deaths per year worldwide [1], affecting more commonly women than men with an age-standardized incidence rate of 1.4 and 0.89 per 100,000 people, respectively [1]. The onset of this disease is characterized by a slow and silent development, resulting in many GBC cases being frequently diagnosed at late stages when patients have a 5-year life expectancy of less than 5% [2]. For this reason, the understanding of how different risk factors influence the early development of gallbladder carcinogenic processes is crucial to improving the prevention strategies for this malignancy.
GBC has multifactorial causes that converge to form a new tumor. The most important risk factor described for GBC development is gallstone disease (GSD) due to its high correlation with GBC [3][4][5][6]. Gallstones can lead to a chronic inflammatory state of tissue damage/regeneration characterized by an imbalance between anti- and pro-inflammatory factors that induce carcinogenic processes in the gallbladder mucosa [6]. In fact, some environmental and lifestyle risk factors may be involved in the development of gallstones and the subsequent GBC formation, such as body mass index (BMI), geographical location, nutritional aspects (high-fat and high-sugar diets), bacterial infections (e.g., Salmonella typhi), chronic diseases (e.g., sclerosing cholangitis, type II diabetes, metabolic syndrome and/or dyslipidemias), parasitic infections, smoking, and alcohol consumption [2][7][8][9][10][11][12][13][14][15][16].

2. Nutritional and Lifestyle Aspects That Increase Susceptibility to Gallbladder Carcinogenesis

As previously mentioned, gallstone disease (GSD) is one of the most important predisposing factors to developing GBC. Thus, metabolic syndrome and some factors that increase the probability of forming gallstones, including sedentary lifestyle, the consumption of sugar-sweetened and artificially sweetened beverages, obesity, high-fat diet, hypercholesterolemia, and the consumption of red meat, can consequently promote carcinogenesis by inducing a chronic pro-inflammatory state in the gallbladder tissue [2][6][17][18]. Conversely, a physically active lifestyle and the consumption of some vegetables, such as radish and sweet potato, have been shown to reduce the risk of developing gallstones and GBC [17][19]. In this regard, an increased BMI constitutes an important risk factor for GBC and other types of cancer [20][21]. For instance, a study by Barahona et al. showed that BMI has a causal effect on gallstone disease, which subsequently increases the GBC risk. The meta-analysis performed by Tan et al. showed that the relative risk of GBC was 1.14 (95% CI, 1.04–1.25) for overweight people (BMI 25–30 kg/m2) and 1.56 (95% CI, 1.41–1.73) for obese individuals (BMI > 30 kg/m2), evidencing a higher GBC risk in women than men [22]. This difference between genders could be explained by the fact that estrogens promote a greater cholesterol storage in the bile, which is consistent with the higher obesity and BMI rates observed in women, and the increased risk of developing gallstones [23]. Interestingly, higher C-reactive protein (CRP) concentrations increased GBC risk in the European population, suggesting that the inflammatory status is crucial in developing GBC [24].
The matter of a sedentary lifestyle can be explained according to metabolic disorders inferred from the study by Skoumas et al., in which physically active women had significantly lower levels of total serum cholesterol, LDL-c, oxidized LDL cholesterol, and triglycerides compared to sedentary women [19]. Other studies have also observed that a more sedentary lifestyle is directly correlated with the risk of developing metabolic syndrome and elevated plasma levels of triglycerides and cholesterol [25][26]. On the other hand, the consumption of sugar-sweetened and artificially sweetened beverages can significantly increase (double) the risk of GBC when individuals consume two or more servings per day (200 mL/serving) of sweetened beverages compared to those without consumption (hazard ratio = 2.24; 95% CI = 1.02 to 4.89) [27]. A probable explanation for this is that the increased sugar intake has been associated with increased body weight and diabetes mellitus, predisposing to gallstone disease-dependent GBC [28]. In fact, diabetic patients have shown a higher risk of GBC compared to non-diabetic individuals [13]. This phenomenon is probably due to the fact that hyperinsulinemia caused by sugar ingestion induces the expression of the insulin-like growth factor receptor (IGFR-1), which is able to induce malignant properties in several types of cancer by increasing cell proliferation, tumorigenic capacity, and apoptosis resistance through the activation of PI3K and MAPK pathways [29].
In general, these data suggest that a sedentary lifestyle and sugar consumption—powered by high-fat food—can promote gallstone formation and subsequently GBC.
About 80% of gallstones are comprised of cholesterol; hence, patients with permanently high levels of plasma cholesterol are candidates for gallstones [30][31][32][33]. Physiologically, cholesterol is transported through different lipoproteins such as high-density lipoproteins (HDL-c) and low-density lipoproteins (LDL-c). HDL-c takes the cholesterol from peripheral tissues through ABC transporters (e.g., ABCA1) and esterifies it through lecithin cholesterol acyltransferase (LCAT) [34]. Subsequently, HDL-c can be recognized by the scavenger receptor class B type I (SR-BI), which facilitates the uptake of high-density lipoprotein cholesterol esters in the liver. In addition, cholesterol can be transported to very-low-density lipoproteins (VLDL-c) via the cholesteryl ester transfer protein (CETP) [35][36]. Then, VLDL-c is transformed into LDL-c and is recognized by the low-density lipoprotein receptor (LDLr) and LDL-related protein (LRP) to induce the internalization of cholesterol into the hepatocytes in the liver [35][37]. Finally, the cholesterol within the hepatocytes can be used in bile formation to be transported to the bile canaliculus and stored in the gallbladder [35][38]. Interestingly, a study by Selcuk Atamanalp et al. showed that high cholesterol and LDL-c levels in plasma were closely correlated with a higher presence of cholesterol gallstones. Conversely, low serum HDL levels did not affect the occurrence of cholesterol gallstones [39]. In addition, Wang et al. showed that patients with increased plasma levels of cholesterol, triglycerides, HDL-c, LDL-c, and apolipoprotein B (APOB), also showed a significantly higher recurrence of gallstones compared to control patients [40], which was similar to those results found by Hayat et al., who showed that patients with gallstones had significantly higher plasma levels of triglycerides and HDL-c than the control patients [41]. All these data reaffirm the idea that high plasma levels of cholesterol and other lipids induce gallstone formation and, therefore, are heavily involved in the subsequent development of GBC. The cholesterol metabolism and its implication in the risk of developing GSD are represented in Figure 1.
Figure 1. The cholesterol metabolism and the risk of developing gallstones. Left: Under normal conditions, cholesterol stored in peripheral tissues is transported to HDL-c via ABC transporters. The circulating HDL-c in the blood transports cholesterol to VLDL-c which is then transformed into LDL-c. Then, LDL-c transports cholesterol to the hepatocytes through a low-density lipoprotein receptor (LDLr). Cholesterol can be used in bile formation and stored in the gallbladder. Right: As a result of a high-fat diet and sedentary lifestyle, the concentration of plasma cholesterol increases, provoking a greater presence of cholesterol in peripheral tissues. This causes increased transportation of cholesterol from peripheral tissues to the liver via the different lipoproteins (HDL-c, VLDL-c, and LDL-c). Finally, this induces an increase in the storage of cholesterol in the liver and subsequently a greater release of cholesterol from the liver to the gallbladder, which leads to a high risk of gallstone formation.
There are different pathophysiological processes that promote gallstone formation, including cholesterol crystallization/nucleation, alteration in mucin secretion, changes in biliary motility, alteration in intestinal cholesterol transport, and intestinal motility [18]. Normally, cholesterol is found in unilamellar vesicles that bind bile salts to allow cholesterol solubilization. However, when there is an increase in cholesterol deposits, the solubilizing capacity of the bile is saturated promoting the solidification and subsequent nucleation of cholesterol/bile acids, allowing the formation of gallstones [42]. The mechanism by which cholelithiasis predisposes to GBC has not yet been established; however, it has been reported that the DNA mutation rate is higher in the inflammation microenvironment induced by gallstones than in normal tissues, increasing the risk of developing GBC [43]. This inflammatory state is generated in different ways, including the direct damage by gallstones due to continuous friction with the mucosa, which leads to a continuous damage/repair loop in the gallbladder epithelium and, on the other hand, the increase in gallstone size which can obstruct the bile duct, which also increases the susceptibility to infections that give rise to the inflammation process [18][44].
Different animal models have been used to study gallstone formation and its effect on the development of preneoplastic lesions [45][46][47][48]. The researchers research group established an animal model of gallbladder preneoplasia through a lithogenic diet. The results showed that after administration of a high-cholesterol diet (lithogenic diet) for 9 months, early gallstone formation was induced within the gallbladder. Furthermore, animals fed a lithogenic diet evidenced fatty liver and higher plasma cholesterol levels than animals fed a normal diet in a similar manner to that observed in humans. More interestingly, those animals treated with a lithogenic diet had metaplastic and dysplastic architecture in gallbladder tissues, with no invasive features, but with a well-defined inflammatory component showing a predominance of lymphocytes and polymorphonuclear cells [47]. A similar study showed that mice treated with a lithogenic diet had epithelial hyperplasia along with the occurrence of acute and chronic inflammation characterized by the presence of eosinophils, neutrophils, and lymphocytes within the lamina propria [48]. Recently, Kato et al. described an animal model generated by the orthotopic implantation of gallbladder organoids containing mutant loss of KRAS and TP53 genes developed in vitro using lentiviral Cre transduction and CRISPR/Cas9 gene editing, respectively. The data showed that the tumor transcriptomic profiles are similar to that found in human tissues, as well as the immune cell infiltration observed during tumor formation, suggesting that this model could be an interesting approach to study carcinogenesis in GBC [49].
Different inflammatory components have been described as participants in the pathophysiology of inflammation including some inflammatory cytokines such as IL-6, IL-10, IL-12, and visfatin. Interestingly, visfatin is considered a key molecule in the activation of human leukocytes and the production of pro-inflammatory cytokines; therefore, it seems to be associated with the risk of developing gallstones [50][51]. In this regard, patients with acute cholecystitis often present a higher expression of visfatin in peripheral blood mononuclear cells (PBMCs), serum, and in grossly inflamed gallbladder tissues. Moreover, the gene overexpression of visfatin observed on in vitro models of acute cholecystitis has been frequently accompanied by an increased expression of other pro-inflammatory mediators including IL-10, TNF-α, IL-6, ICAM-1, and VCAM-1 [52]. Similarly, Nien Wang et al. showed that serum visfatin levels were markedly higher in subjects that presented pigment and cholesterol gallstones than in healthy controls. Additionally, serum levels of cholesterol, triglycerides, AST, ALT, leukocyte count, and fasting glucose were significantly higher in those individuals with gallstones. Interestingly, high AST levels and the increased white blood cell count were considered significant predictors of gallbladder lithiasis, while the elevated values of visfatin in serum were also suggested as a significant risk factor for gallstone formation [51]. These results suggested that visfatin could be a predictive marker of inflammation and predisposition to gallbladder lithiasis.
As previously mentioned, evidence accumulated over many years indicates that gallstones can induce an inflammatory microenvironment that increases the risk of developing GBC. However, this risk can be fostered by a greater genetic predisposition [53], for example, the genetic variability present in genes that encode the different ATP-binding cassette (ABC) transporters in the hepatocanalicular membrane, which are involved in the different processes of the exportation of bile salts in biliary tracts, including the transportation of ABCB11, the transport of phosphatidylcholine (ABCB4), and secretion of cholesterol and phytosterols into bile (heterodimer ABCG5/8) [54]. In this regard, a genetic variant in the ABCG8 gene (variant rs11887534 or D19H) has been associated with a higher gallstone development through cholesterol hypersecretion and cholesterol supersaturation in the bile [53][55]. In addition, other variants (rs1558375, rs17209837, and rs4148808) have been determined in the 7q21.12 region harboring both the ABCB1 and ABCB4 genes, which showed a higher risk of developing GBC [56]. A study by Bustos et al. showed that in the Chilean Mapuche ancestry population, variants in ABCG8 (rs11887534) and TRAF3 (rs12882491) were associated with GSD. In addition, it was shown that TRAF3 levels were lower in individuals affected by GSD, suggesting that these variants could be used as risk markers for GBC [57][58]. Other mutations occur in the ABCB4 gene and are classified as nonsense mutations (class I), missense mutations affecting maturation (class II), activity (class III), or protein stability (class IV), and mutations with no identifiable effect (class V) [59]. It has been shown that mutations in this gene increase the risk of developing gallstones in subjects under 40 years, mainly by inducing an ABCB4 deficiency that results in low biliary phosphatidylcholine concentrations, which is consistent with the spontaneous occurrence of cholecystolithiasis [60][61]. In fact, the homozygous ABCB4 mutations lead to the complete absence of the phospholipid transporter and no secretion of phospholipids into bile, which finally causes a decrease in the solubility of bile, and consequently, a greater predisposition to bile crystallization and gallstone formation [62]. Other mutations and alterations have been described in different genes and proteins potentially involved in a higher risk of developing gallstones, such as ABCB11 [62], cholesterol 7a-hydroxylase (CYPA1) [63][64], APOB gene [65], and cholecystokinin A receptor (CCKAR) [66][67]. In addition, certain alterations in genes related to the immune system, inflammation, and oxidative stress have also been implicated in a greater risk of developing GBC, including mutations in TLR2, TLR4 [68], IL1RN, IL1B [69], IL10, IL8, IL8RB, RNASEL, VEGF [70], and CCR5 [71], as well as rs7504990 variant in the DCC [72]. These data show that the predisposition to developing cholecystolithiasis and GBC also have an important genetic background that needs to be considered in GBC carcinogenesis.
Finally, another risk factor associated with GBC is the appearance of bluish and brittle calcifications in the inner gallbladder wall named "porcelain gallbladder" [73]. Porcelain gallbladder has an incidence of less than 1% in patients with gallbladder disease, being more prevalent in women [73]. This rare condition is considered a risk factor for GBC because approximately 60% to 90% of these cases show gallstones [73][74]. Despite the pathophysiology of "porcelain gallbladder" not being clear, this condition could be a consequence of a previous chronic inflammatory process or could be the result of an obstruction produced by gallstones that induce the accumulation and precipitation of calcium in the mucosal layer of the gallbladder wall [75]. Whatever the origin of this disease, it is also unknown whether calcium levels play a role in the “porcelain gallbladder” pathogenesis. Recently, Berger et al. found significantly higher calcium and parathormone (PTH) levels in the plasma of individuals with porcelain gallbladder compared to controls [76], which suggests that individuals with diseases that induce persistent hypercalcemia (e.g., primary hyperparathyroidism) also have a higher risk of developing porcelain gallbladder. In this regard, the researchers venture to propose that persistent hypercalcemia could be an initiating factor of porcelain gallbladder, which would eventually trigger the formation of a chronic inflammatory state in the inner layer of the gallbladder, increasing in this manner the risk of developing GBC. However, more studies are still needed to demonstrate this hypothesis.
Figure 2 shows the relationship between the risk factors described above and their involvement in GBC inflammation and carcinogenesis.
Figure 2. Carcinogenesis process in gallbladder cancer. The damage caused by the presence of risk factors such as gallstones, infections, lithogenic bile, alcohol, smoking, and genetic predisposition can induce continuous damage in the mucosa of the gallbladder, which is characterized by a chronic inflammatory state mainly highlighted by the activation of macrophages and lymphocytes that leads to the release of pro-inflammatory cytokines (TNF-α, IL-6, IL-1) and ROS stimulating the carcinogenic metaplasia/hyperplasia–dysplasia–carcinoma transition. This process can be marked by different gene alterations and protein expressions such asTP53andFHITmutations and COX-2, TNF-α, and CLDN-18 overexpression, respectively. BMI: Body Mass Index; TNF-α: Tumor necrosis factor-alpha; ROS: Reactive oxygen species; IL-1: Interleukin-1; IL-6; Interleukin-6; CLDN-18: Claudin18; COX-2: Cyclooxygenase 2; TP53: Tumor protein 53; FHIT: Fragile Histidine Triad Diadenosine Triphosphatase. The risk factors in bold mean strong evidence. The risk factor in italics and underlined means weak evidence

This entry is adapted from the peer-reviewed paper 10.3390/jpm12020234

References

  1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249.
  2. Hundal, R.; Shaffer, E.A. Gallbladder cancer: Epidemiology and outcome. Clin Epidemiol 2014, 6, 99–109.
  3. Alvi, A.R.; Siddiqui, N.A.; Zafar, H. Risk factors of gallbladder cancer in Karachi-a case-control study. World J. Surg. Oncol. 2011, 9, 164.
  4. Roa, I.; Ibacache, G.; Roa, J.; Araya, J.; de Aretxabala, X.; Muñoz, S. Gallstones and gallbladder cancer-volume and weight of gallstones are associated with gallbladder cancer: A case-control study. J. Surg. Oncol. 2006, 93, 624–628.
  5. Hsing, A.W.; Gao, Y.-T.; Han, T.-Q.; Rashid, A.; Sakoda, L.C.; Wang, B.-S.; Shen, M.-C.; Zhang, B.-H.; Niwa, S.; Chen, J.; et al. Gallstones and the risk of biliary tract cancer: A population-based study in China. Br. J. Cancer 2007, 97, 1577–1582.
  6. Espinoza, J.A.; Bizama, C.; García, P.; Ferreccio, C.; Javle, M.; Miquel, J.F.; Koshiol, J.; Roa, J.C. The inflammatory inception of gallbladder cancer. Biochim. Et Biophys. Acta (BBA)-Bioenerg. 2016, 1865, 245–254.
  7. Stokes, C.S.; Krawczyk, M.; Lammert, F. Gallstones: Environment, Lifestyle and Genes. Dig. Dis. 2011, 29, 191–201.
  8. Bouvard, V.; Baan, R.; Straif, K.; Grosse, Y.; Secretan, B.; El Ghissassi, F.; Benbrahim-Tallaa, L.; Guha, N.; Freeman, C.; Galichet, L.; et al. A review of human carcinogens—Part B: Biological agents. Lancet Oncol. 2009, 10, 321–322.
  9. Nagaraja, V.; Eslick, G.D. Systematic review with meta-analysis: The relationship between chronicSalmonella typhicarrier status and gall-bladder cancer. Aliment. Pharmacol. Ther. 2014, 39, 745–750.
  10. Zhu, Q.; Sun, X.; Ji, X.; Zhu, L.; Xu, J.; Wang, C.; Zhang, C.; Xue, F.; Liu, Y. The association between gallstones and metabolic syndrome in urban Han Chinese: A longitudinal cohort study. Sci. Rep. 2016, 6, 29937.
  11. van Erp, L.W.; Cunningham, M.; Narasimman, M.; Ali, H.A.; Jhaveri, K.; Drenth, J.P.H.; Janssen, H.L.A.; Levy, C.; Hirschfield, G.M.; Hansen, B.E.; et al. Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps. Liver Int. 2020, 40, 382–392.
  12. Deng, Z.; Xuan, Y.; Li, X.; Crawford, W.J.; Yuan, Z.; Chen, Z.; Brooks, A.; Song, Y.; Wang, H.; Liang, X.; et al. Effect of metabolic syndrome components on the risk of malignancy in patients with gallbladder lesions. J. Cancer 2021, 12, 1531–1537.
  13. Gu, J.; Yan, S.; Wang, B.; Shen, F.; Cao, H.; Fan, J.; Wang, Y. Type 2 diabetes mellitus and risk of gallbladder cancer: A systematic review and meta-analysis of observational studies. Diabetes/Metab. Res. Rev. 2015, 32, 63–72.
  14. Wenbin, D.; Zhuo, C.; Zhibing, M.; Chen, Z.; Ruifan, Y.; Jie, J.; Cheng, Q.; Zhenming, G. The effect of smoking on the risk of gallbladder cancer: A meta-analysis of observational studies. Eur. J. Gastroenterol. Hepatol. 2013, 25, 373–379.
  15. Yagyu, K.; Kikuchi, S.; Obata, Y.; Lin, Y.; Ishibashi, T.; Kurosawa, M.; Inaba, Y.; Tamakoshi, A.; JACC Study Group. Cigarette smoking, alcohol drinking and the risk of gallbladder cancer death: A prospective cohort study in Japan. Int. J. Cancer 2008, 122, 924–929.
  16. McGee, E.E.; Jackson, S.S.; Petrick, J.L.; Van Dyke, A.L.; Adami, H.-O.; Albanes, D.; Andreotti, G.; Beane-Freeman, L.E.; De Gonzalez, A.B.; Buring, J.E.; et al. Smoking, Alcohol, and Biliary Tract Cancer Risk: A Pooling Project of 26 Prospective Studies. J. Natl. Cancer Inst. 2019, 111, 1263–1278.
  17. Pandey, M.; Shukla, V.K. Diet and gallbladder cancer: A case-control study. Eur. J. Cancer Prev. 2002, 11, 365–368.
  18. Di Ciaula, A.; Portincasa, P. Recent advances in understanding and managing cholesterol gallstones. F1000Res 2018, 7.
  19. Skoumas, J.; Pitsavos, C.; Panagiotakos, D.B.; Chrysohoou, C.; Zeimbekis, A.; Papaioannou, I.; Toutouza, M.; Toutouzas, P.; Stefanadis, C. Physical activity, high density lipoprotein cholesterol and other lipids levels, in men and women from the ATTICA study. Lipids Health Dis. 2003, 2, 3.
  20. Renehan, A.G.; Tyson, M.; Egger, M.; Heller, R.F.; Zwahlen, M. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371, 569–578.
  21. Hsing, A.W.; Sakoda, L.C.; Rashid, A.; Chen, J.; Shen, M.C.; Han, T.Q.; Wang, B.S.; Gao, Y.T. Body size and the risk of biliary tract cancer: A population-based study in China. Br. J. Cancer 2008, 99, 811–815.
  22. Tan, W.; Gao, M.; Liu, N.; Zhang, G.; Xu, T.; Cui, W. Body Mass Index and Risk of Gallbladder Cancer: Systematic Review and Meta-Analysis of Observational Studies. Nutrients 2015, 7, 8321–8334.
  23. Everson, G.T.; McKinley, C.; Kern, F. Mechanisms of gallstone formation in women. Effects of exogenous estrogen (Premarin) and dietary cholesterol on hepatic lipid metabolism. J. Clin. Invest. 1991, 87, 237–246.
  24. Barahona Ponce, C.; Scherer, D.; Brinster, R.; Boekstegers, F.; Marcelain, K.; Gárate-Calderón, V.; Müller, B.; de Toro, G.; Retamales, J.; Barajas, O.; et al. Gallstones, Body Mass Index, C-Reactive Protein, and Gallbladder Cancer: Mendelian Randomization Analysis of Chilean and European Genotype Data. Hepatology 2021, 73, 1783–1796.
  25. Pinto Pereira, S.M.; Ki, M.; Power, C. Sedentary behaviour and biomarkers for cardiovascular disease and diabetes in mid-life: The role of television-viewing and sitting at work. PLoS ONE 2012, 7, e31132.
  26. Crichton, G.E.; Alkerwi, A. Physical activity, sedentary behavior time and lipid levels in the Observation of Cardiovascular Risk Factors in Luxembourg study. Lipids Health Dis. 2015, 14, 87.
  27. Larsson, S.C.; Giovannucci, E.L.; Wolk, A. Sweetened Beverage Consumption and Risk of Biliary Tract and Gallbladder Cancer in a Prospective Study. J. Natl. Cancer Inst. 2016, 108.
  28. Borena, W.; Edlinger, M.; Bjørge, T.; Häggström, C.; Lindkvist, B.; Nagel, G.; Engeland, A.; Stocks, T.; Strohmaier, S.; Manjer, J.; et al. A prospective study on metabolic risk factors and gallbladder cancer in the metabolic syndrome and cancer (Me-Can) collaborative study. PLoS ONE 2014, 9, e89368.
  29. Arcidiacono, B.; Iiritano, S.; Nocera, A.; Possidente, K.; Nevolo, M.T.; Ventura, V.; Foti, D.; Chiefari, E.; Brunetti, A. Insulin resistance and cancer risk: An overview of the pathogenetic mechanisms. Exp. Diabetes Res. 2012, 2012, 789174.
  30. Van Erpecum, K.J. Pathogenesis of cholesterol and pigment gallstones: An update. Clin. Res. Hepatol. Gastroenterol. 2011, 35, 281–287.
  31. Rebholz, C.; Krawczyk, M.; Lammert, F. Genetics of gallstone disease. Eur. J. Clin. Invest. 2018, 48, e12935.
  32. Ryu, S.; Chang, Y.; Yun, K.E.; Jung, H.S.; Shin, J.H.; Shin, H. Gallstones and the Risk of Gallbladder Cancer Mortality: A Cohort Study. Am. J. Gastroenterol. 2016, 111, 1476–1487.
  33. Stinton, L.M.; Shaffer, E.A. Epidemiology of gallbladder disease: Cholelithiasis and cancer. Gut Liver 2012, 6, 172–187.
  34. Rousset, X.; Vaisman, B.; Amar, M.; Sethi, A.A.; Remaley, A.T. Lecithin: Cholesterol acyltransferase--from biochemistry to role in cardiovascular disease. Curr. Opin. Endocrinol. Diabetes Obes. 2009, 16, 163–171.
  35. Masson, D.; Jiang, X.C.; Lagrost, L.; Tall, A.R. The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. J. Lipid Res. 2009, 50, S201–S206.
  36. Acton, S.; Rigotti, A.; Landschulz, K.T.; Xu, S.; Hobbs, H.H.; Krieger, M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996, 271, 518–520.
  37. Barter, P.J.; Brewer, H.B.; Chapman, M.J.; Hennekens, C.H.; Rader, D.J.; Tall, A.R. Cholesteryl ester transfer protein: A novel target for raising HDL and inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 160–167.
  38. Rader, D.J. Regulation of reverse cholesterol transport and clinical implications. Am. J. Cardiol. 2003, 92, 42J–49J.
  39. Atamanalp, S.S.; Keles, M.S.; Atamanalp, R.S.; Acemoglu, H.; Laloglu, E. The effects of serum cholesterol, LDL, and HDL levels on gallstone cholesterol concentration. Pak. J. Med. Sci. 2013, 29, 187–190.
  40. Wang, J.; Shen, S.; Wang, B.; Ni, X.; Liu, H.; Yu, R.; Suo, T. Serum lipid levels are the risk factors of gallbladder stones: A population-based study in China. Lipids Health Dis. 2020, 19, 50.
  41. Hayat, S.; Hassan, Z.; Changazi, S.H.; Zahra, A.; Noman, M.; Zain Ul Abdin, M.; Javed, H.; Ans, A.H. Comparative analysis of serum lipid profiles in patients with and without gallstones: A prospective cross-sectional study. Ann. Med. Surg. 2019, 42, 11–13.
  42. Reshetnyak, V.I. Concept of the pathogenesis and treatment of cholelithiasis. World J. Hepatol. 2012, 4, 18–34.
  43. Shrikhande, S.V.; Barreto, S.G.; Singh, S.; Udwadia, T.E.; Agarwal, A.K. Cholelithiasis in gallbladder cancer: Coincidence, cofactor, or cause! Eur. J. Surg. Oncol. 2010, 36, 514–519.
  44. Kuraishy, A.; Karin, M.; Grivennikov, S.I. Tumor promotion via injury- and death-induced inflammation. Immunity 2011, 35, 467–477.
  45. Jang, S.I.; Fang, S.; Kim, K.P.; Ko, Y.; Kim, H.; Oh, J.; Hong, G.Y.; Lee, S.Y.; Kim, J.M.; Noh, I.; et al. Combination treatment with n-3 polyunsaturated fatty acids and ursodeoxycholic acid dissolves cholesterol gallstones in mice. Sci. Rep. 2019, 9, 12740.
  46. Maurer, K.J.; Rao, V.P.; Ge, Z.; Rogers, A.B.; Oura, T.J.; Carey, M.C.; Fox, J.G. T-cell function is critical for murine cholesterol gallstone formation. Gastroenterology 2007, 133, 1304–1315.
  47. Rosa, L.; Lobos-González, L.; Muñoz-Durango, N.; García, P.; Bizama, C.; Gómez, N.; González, X.; Wichmann, I.A.; Saavedra, N.; Guevara, F.; et al. Evaluation of the chemopreventive potentials of ezetimibe and aspirin in a novel mouse model of gallbladder preneoplasia. Mol. Oncol. 2020, 14, 2834–2852.
  48. Lavoie, B.; Nausch, B.; Zane, E.A.; Leonard, M.R.; Balemba, O.B.; Bartoo, A.C.; Wilcox, R.; Nelson, M.T.; Carey, M.C.; Mawe, G.M. Disruption of gallbladder smooth muscle function is an early feature in the development of cholesterol gallstone disease. Neurogastroenterol. Motil. 2012, 24, e313–e324.
  49. Kato, S.; Fushimi, K.; Yabuki, Y.; Maru, Y.; Hasegawa, S.; Matsuura, T.; Kurotaki, D.; Suzuki, A.; Kobayashi, N.; Yoneda, M.; et al. Precision modeling of gall bladder cancer patients in mice based on orthotopic implantation of organoid-derived tumor buds. Oncogenesis 2021, 10, 33.
  50. Liu, Z.; Kemp, T.J.; Gao, Y.T.; Corbel, A.; McGee, E.E.; Wang, B.; Shen, M.C.; Rashid, A.; Hsing, A.W.; Hildesheim, A.; et al. Association of circulating inflammation proteins and gallstone disease. J. Gastroenterol. Hepatol. 2018, 33, 1920–1924.
  51. Moschen, A.R.; Kaser, A.; Enrich, B.; Mosheimer, B.; Theurl, M.; Niederegger, H.; Tilg, H. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J. Immunol. 2007, 178, 1748–1758.
  52. Park, J.W.; Kim, O.H.; Lee, S.C.; Kim, K.H.; Hong, H.E.; Seo, H.; Choi, H.J.; Kim, S.J. Serum level of visfatin can reflect the severity of inflammation in patients with acute cholecystitis. Ann. Surg. Treat. Res. 2020, 99, 26–36.
  53. Grünhage, F.; Acalovschi, M.; Tirziu, S.; Walier, M.; Wienker, T.F.; Ciocan, A.; Mosteanu, O.; Sauerbruch, T.; Lammert, F. Increased gallstone risk in humans conferred by common variant of hepatic ATP-binding cassette transporter for cholesterol. Hepatology 2007, 46, 793–801.
  54. Small, D.M. Role of ABC transporters in secretion of cholesterol from liver into bile. Proc Natl Acad Sci USA 2003, 100, 4–6.
  55. Von Kampen, O.; Buch, S.; Nothnagel, M.; Azocar, L.; Molina, H.; Brosch, M.; Erhart, W.; von Schönfels, W.; Egberts, J.; Seeger, M.; et al. Genetic and functional identification of the likely causative variant for cholesterol gallstone disease at the ABCG5/8 lithogenic locus. Hepatology 2013, 57, 2407–2417.
  56. Mhatre, S.; Wang, Z.; Nagrani, R.; Badwe, R.; Chiplunkar, S.; Mittal, B.; Yadav, S.; Zhang, H.; Chung, C.C.; Patil, P.; et al. Common genetic variation and risk of gallbladder cancer in India: A case-control genome-wide association study. Lancet Oncol. 2017, 18, 535–544.
  57. Bustos, B.I.; Pérez-Palma, E.; Buch, S.; Azócar, L.; Riveras, E.; Ugarte, G.D.; Toliat, M.; Nürnberg, P.; Lieb, W.; Franke, A.; et al. Variants in ABCG8 and TRAF3 genes confer risk for gallstone disease in admixed Latinos with Mapuche Native American ancestry. Sci. Rep. 2019, 9, 772.
  58. Jackson, S.S.; Van De Wyngard, V.; Pfeiffer, R.M.; Cook, P.; Hildesheim, A.; Pinto, L.A.; Jackson, S.H.; Choi, K.; Verdugo, R.A.; Cuevas, M.; et al. Inflammatory profiles in Chilean Mapuche and non-Mapuche women with gallstones at risk of developing gallbladder cancer. Sci. Rep. 2021, 11, 3686.
  59. Delaunay, J.L.; Durand-Schneider, A.M.; Dossier, C.; Falguières, T.; Gautherot, J.; Davit-Spraul, A.; Aït-Slimane, T.; Housset, C.; Jacquemin, E.; Maurice, M. A functional classification of ABCB4 variations causing progressive familial intrahepatic cholestasis type 3. Hepatology 2016, 63, 1620–1631.
  60. Nakeeb, A.; Comuzzie, A.G.; Martin, L.; Sonnenberg, G.E.; Swartz-Basile, D.; Kissebah, A.H.; Pitt, H.A. Gallstones: Genetics versus environment. Ann. Surg. 2002, 235, 842–849.
  61. Rosmorduc, O.; Hermelin, B.; Boelle, P.Y.; Parc, R.; Taboury, J.; Poupon, R. ABCB4 gene mutation-associated cholelithiasis in adults. Gastroenterology 2003, 125, 452–459.
  62. Jansen, P.L.; Strautnieks, S.S.; Jacquemin, E.; Hadchouel, M.; Sokal, E.M.; Hooiveld, G.J.; Koning, J.H.; De Jager-Krikken, A.; Kuipers, F.; Stellaard, F.; et al. Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology 1999, 117, 1370–1379.
  63. Pullinger, C.R.; Eng, C.; Salen, G.; Shefer, S.; Batta, A.K.; Erickson, S.K.; Verhagen, A.; Rivera, C.R.; Mulvihill, S.J.; Malloy, M.J.; et al. Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J. Clin. Invest. 2002, 110, 109–117.
  64. Miyake, J.H.; Duong-Polk, X.T.; Taylor, J.M.; Du, E.Z.; Castellani, L.W.; Lusis, A.J.; Davis, R.A. Transgenic expression of cholesterol-7-alpha-hydroxylase prevents atherosclerosis in C57BL/6J mice. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 121–126.
  65. Lancellotti, S.; Zaffanello, M.; Di Leo, E.; Costa, L.; Lonardo, A.; Tarugi, P. Pediatric gallstone disease in familial hypobetalipoproteinemia. J. Hepatol. 2005, 43, 188–191.
  66. Miller, L.J.; Holicky, E.L.; Ulrich, C.D.; Wieben, E.D. Abnormal processing of the human cholecystokinin receptor gene in association with gallstones and obesity. Gastroenterology 1995, 109, 1375–1380.
  67. Wang, D.Q.; Schmitz, F.; Kopin, A.S.; Carey, M.C. Targeted disruption of the murine cholecystokinin-1 receptor promotes intestinal cholesterol absorption and susceptibility to cholesterol cholelithiasis. J. Clin. Invest. 2004, 114, 521–528.
  68. Srivastava, K.; Srivastava, A.; Kumar, A.; Mittal, B. Significant association between toll-like receptor gene polymorphisms and gallbladder cancer. Liver Int. 2010, 30, 1067–1072.
  69. Vishnoi, M.; Pandey, S.N.; Choudhuri, G.; Mittal, B. IL-1 gene polymorphisms and genetic susceptibility of gallbladder cancer in a north Indian population. Cancer Genet. Cytogenet. 2008, 186, 63–68.
  70. Hsing, A.W.; Sakoda, L.C.; Rashid, A.; Andreotti, G.; Chen, J.; Wang, B.S.; Shen, M.C.; Chen, B.E.; Rosenberg, P.S.; Zhang, M.; et al. Variants in inflammation genes and the risk of biliary tract cancers and stones: A population-based study in China. Cancer Res. 2008, 68, 6442–6452.
  71. Srivastava, A.; Pandey, S.N.; Choudhuri, G.; Mittal, B. CCR5 Delta32 polymorphism: Associated with gallbladder cancer susceptibility. Scand. J. Immunol. 2008, 67, 516–522.
  72. Cha, P.C.; Zembutsu, H.; Takahashi, A.; Kubo, M.; Kamatani, N.; Nakamura, Y. A genome-wide association study identifies SNP in DCC is associated with gallbladder cancer in the Japanese population. J. Hum. Genet. 2012, 57, 235–237.
  73. Stephen, A.E.; Berger, D.L. Carcinoma in the porcelain gallbladder: A relationship revisited. Surgery 2001, 129, 699–703.
  74. Morimoto, M.; Matsuo, T.; Mori, N. Management of Porcelain Gallbladder, Its Risk Factors, and Complications: A Review. Diagnostics 2021, 11, 1073.
  75. Lam, R.; Zakko, A.; Petrov, J.C.; Kumar, P.; Duffy, A.J.; Muniraj, T. Gallbladder Disorders: A Comprehensive Review. Dis. Mon. 2021, 67, 101130.
  76. Berger, M.; Dy, B.; McKenzie, T.; Thompson, G.; Wermers, R.; Lyden, M. Rates of hypercalcemia and hyperparathyroidism among patients with porcelain gallbladder. Am. J. Surg. 2020, 220, 127–131.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback